Bio-oss结合Bio-gide修复牙种植体周围骨缺损的组织学研究

目的：通过制作带有种植体的硬组织磨片,评价无机牛骨(deproteinized natural bovine mineral,Bio-oss)结合可吸收性胶原膜(bioresorbable collagen mambrane,Bio-gide)在牙种植体周围骨缺损中的引导骨再生作用及效果。方法：在免股骨植入羟基磷灰石涂层BLB种植体,并在其外侧壁制造标准骨缺损,A组在骨缺损处植入Bio-oss颗粒并在其表面覆盖Bio-gidt,膜,B组作为空白对照,分别于术后1、2、4、6个月取样品,通过带种植体的硬组织切片进行骨组织形态学分析。结果：术后1个月Bio-oss颗粒表面有新骨形成,随时间延长Bio-oss发生降解吸收,新生骨量增加,并与种植体表面形成骨性结合。结论：可吸收性胶原膜Bio-gide结合Bio-oss应用于牙种植体周围骨缺损中,可以引导骨组织再生,重建缺损的骨组织,新生骨与种植体形成骨性结合。     

可吸收性胶原膜结合无机牛骨修复种植牙骨缺损的临床研究

目的：应用可吸收性生物膜Bio-gide结合无机牛骨Bio-oss修复临床牙种植中的骨缺损，解决种植区的骨量不足问题。方法：在牙种植外科中将Bin-oss充填在暴露的种植体周围，表面覆盖可吸收性胶原膜Bio-gide，6个月后进行二期手术，暴露骨缺损区，观察并测量骨缺损的修复情况，并通过临床检查及x线曲面断层片，评价其在临床种植体周围骨缺损中引导骨组织再生的效果。结果：二期手术发现骨缺损区都获得了高水平的新骨形成，骨缺损重建百分率达90％。术后及承载6-36个月的跟踪随访，结果显示88个植入骨缺损区的ITI种植体，有2颗脱落，种植体存活率达97％。结论：Bio-oss与Bio-gide联合应用于临床ITI种植体周围骨缺损，可以成功的引导骨组织再生，重建缺损的骨组织，新生骨与种植体形成骨性结合。     

钛膜和胶原膜联合应用引导种植体周骨缺损骨再生的临床研究

目的：评价钛膜与胶原膜联合应用引导种植体骨缺损骨再生的临床效果。方法：将34颗种植体植入30例患者的狭窄形牙槽嵴或唇颊骨壁缺损拔牙窝,所有种植体的唇、颊侧面部分暴露,种植体周骨缺损空间维持能力较差。测量种植暴露部分的最大长度,将羟基磷灰石珊瑚骨粉置于骨缺损处,采用钛膜覆盖稳定骨移植材料,然后将胶原膜覆盖于钛膜表面,无张力缝合伤口,术后6个月行Ⅱ期手术,取下钛膜,检查骨缺损骨再生的状况,再次测量种植暴露部分的最大长度。结果：2例患者于手术3个月左右因钛膜局部暴露,将钛膜取出。钛膜暴露率为6.6%。术后6个月Ⅱ期手术时见,所有种植体暴露部分完全被再生骨覆盖,种植体暴露部分长度为0。结论：在空间维持能力较差的骨缺损处,钛膜和胶原膜联合应用引导骨再生可获得理想结果。钛膜和胶原膜联合应用可显著降低钛膜的暴露率,延迟发生膜暴露的时间,从而使引导骨再生的结果更加具有可预测性。     

Bio-Gide生物膜引导再生骨中种植体短期成功率的临床回顾

目的：评估141例通过Bio-Gide生物膜引导的再生骨中种植和负重的259枚种植体的成功率方法：选择种植术区存在骨缺损，可通过GBR技术修复骨缺损的患者141例其中123例202枚种植体周存在水平向骨吸收，种植体通过GBR可同期植入；18例57枚种植体周骨缺损量较大，存在垂直向多壁骨缺损，需先通过GBR技术引导新骨生成，6—8个月后再植入种植体。生物膜均采用可吸收性的Bio—Gide膜，骨移植物为自体骨与Bio—OSS骨粉的混合物术后1、3、6月进行X光检查及临床检查。二期手术时，对新生骨组织量进行评估：种植修复体完成后，分别于戴牙后6、12、24月定期复诊，检查种植体周围骨组织的吸收及种植体周围软组织情况：结果：二期手术时，141例253枚种植体均已与骨组织形成理想的骨结合，6枚种植体周围形成纤维愈合而失败，后经重新种植，所有种植体均顺利完成种植义齿修复。修复后随访6—24个月，种植体均能成功地恢复咬he功能。结论：Bio—Gide生物膜引导再生骨中种植体成功率为96．9％，与正常骨组织中种植修复的成功率不存在明显差异。     

引导骨组织再生技术在牙种植修复中的临床应用研究

目的 评价引导骨再生技术在牙种植中引导骨再生修复的方法和效果。方法 对80例牙槽骨骨缺损的患者采用植Bio-Oss小牛骨粉，盖Bib-Gide膜或钛膜，进行引导骨再生，修复骨缺损并行骨内种植体周的骨增量。结果 80例患者共植入90枚种植体，38例采用钛膜，42例采用Bio-Gide胶原膜；术后部份患者伤口裂开、膜暴露；Bio-Gide膜与钛膜的伤口裂开发生率分别为7．1％与21．1％。二期手术时观察膜下骨再生情况，无感染患者膜下的新骨生成较膜暴露者多，Bio-Gide胶原膜暴露后自行愈合情况较使用钛膜者理想。88枚种植体成功地完成骨整合并成功完成义齿修复，2枚种植体因钛膜暴露及感染失败。结论 Bio-Gide胶原膜及钛膜皆能有效地屏蔽软组织，引导骨再生，重建牙槽骨外形；术后无伤口裂开、膜暴露者有较好的骨再生效果；与钛膜相比，Bio-Gide胶原膜更为简便易用，出现过早裂开的比率也较少。     

钛膜和胶原膜联合应用引导种植体周骨缺损骨再生的临床研究

目的:评价钛膜与胶原膜联合应用引导骨缺损骨再生的临床效果.方法:将34颗种植体植入30例患者的狭窄形牙槽嵴或唇颊骨壁缺损拔牙窝,所有种植体的唇、颊侧面部分暴露,种植体周骨缺损空间维持能力较差.测量种植暴露部分的最大长度,将羟基磷灰石珊瑚骨粉置于骨缺损处,采用钛膜覆盖稳定骨移植材料,然后将胶原膜覆盖于钛膜表面,无张力缝合伤口,术后六个月行Ⅱ期手术,取下钛膜,检查骨缺损骨再生的状况,再次测量种植暴露部分的最大长度.结果:2例患者于手术3个月左右因钛膜局部暴露,将钛膜取出.钛膜暴露率为6.6%.术后6个月Ⅱ期手术时见,所有种植体暴露部分完全被再生骨覆盖,种植体暴露部分长度为0.结论:在空间维持能力较差的骨缺损处,钛膜和胶原膜联合应用引导骨再生可获得理想结果.钛膜和胶原膜联合应用可显著降低钛膜的暴露率,延迟发生膜暴露的时间,从而使引导骨再生的结果更加具有可预测性.     

骨引导再生技术在种植体周围牙槽嵴重建中的应用

目的：探讨种植体周围牙槽嵴的重建方式。方法：植A种植体高出牙槽顶骨面，在其周围植入Bio-oss骨粉，以盖嵴式覆以Bio—Gide膜，钛钉固定。分别于术后3、6、8月。通过，临床、X线检查和二期术，观察创面与种植体和周围骨组织结合情况以及牙槽嵴成骨情况。结果：显效34例49枚种植体，无效3例3枚种植体。结论：骨引导再生术可有效重建种植体周围牙槽嵴．     

钛膜引导骨再生在骨内种植体植入中的应用

目的：总结牙种植术后使用钛膜引导骨再生临床体会。方法：对30例47枚牙种植术中发现骨缺损、骨量不足的患者采用钛膜进行骨引导再生修复骨缺损及骨增量。术后定期观察，对新骨生长情况进行连续临床和X线的观察分析。结果：30例47枚牙种植术中，39枚种植体植入部位使用了钛膜。二期手术时种植体均已与骨组织形成理想的骨融合，顺利完成种植义齿修复。39枚种植体中有15枚种植体术后2个月的X线片可见到种植体封闭螺帽上方骨密度增高影。4月后二期手术切开牙龈时可见到新骨覆盖种植体表面，以骨凿等去除新骨后方可见到封闭螺帽。结论：医用钛膜在种植术中应用有较好的引导骨再生作用，有利于种植术后骨融合期新骨的形成。不可吸收性膜的一些固有缺陷可通过临床正确的设计关在术中严格按照操作要点进行手术，可获得理想的骨再生效果。     

BIO-OSS和BIO-GIDE在骨量不足的牙种植术中的运用

目的：通过应用BIO-OSS骨移植和BIO-GIDE引导骨再生技米于牙种植术中，观察其促进部分缺失牙槽骨再生的临床效果。方法：选择拔牙区颊侧骨扳萎缩吸收或牙槽骨缺损的患者作为研究的对象，在行种植体植入的同时行骨粉充填或在植牙前先行骨粉充填骨缺损区，再用胶原再生膜覆盖在骨移植材料上或颊侧种植体暴露和骨面，观察骨组织再生情况及种植体的稳定性。结果：1-3年的放射学和临床观察，表现为种植体周骨组织或骨缺损区骨组织有不同程度的再生，种植体稳固。结论：骨移植和引导骨再生技术用于治疗牙槽骨板萎缩吸收或缺损的患者。有提高牙种植成功率、扩大适应症的作用。     

聚羟基丁酸酯膜引导即刻植入种植体周围骨组织再生的研究

目的：评价聚羟基丁酸酯（ＰＨＢ）膜引导种植体周围骨组织再生的效果。方法：在狗下颌骨即刻植入种植体的颊侧形成骨缺损,覆盖ＰＨＢ膜,与钛膜及空白对照比较,术后１、２、３个月分别取标本,采用大体观察、Ｘ线摄片、组织学、四环素荧光标记方法观察骨组织再生情况。结果：ＰＨＢ膜组种植体周围骨缺损区较空白组有更多的新生骨充填,加速了骨再生过程,与钛膜组类似。结论：ＰＨＢ有良好的生物相容性,可以用作骨组织引导再生膜     

自体骨碎末与复合移植修复种植体周围骨缺损的比较研究

目的：研究自体骨碎末与混入Bio-Oss复合移植修复种植体周围骨缺损的效果。方法：9周及16周后对种植体周围骨缺损处植入自体骨末、自体骨末与Bio-Oss二者1：1混合骨末及未植骨进行比较。结果：植入的自体骨碎末恢复了一定的骨缺损,混合Bio—Oss组恢复最佳。各组16周时骨整合均优于9周。结论：植入钻孔时收集的自体骨碎末对于恢复种植体周围少量的骨缺损,是完全可行的。自体骨碎末作为供骨量不足时,可以混合适当的Bio—Oss颗粒行复合移植,效果更为理想。     

Demineralization of the Contacting Surfaces in Autologous Onlay Bone Grafts Improves Bone Formation and Bone Consolidation

Background: Autologous bone grafts are usually well consolidated after 4 to 5 months but can be incompletely interlocked with the native bone. This study investigated the effect of acid demineralization of the graft–bed interface on graft consolidation. Methods: Onlay bone grafts were performed on the calvaria of 36 guinea pigs. Half of the animals had the graft–bed contacting surfaces demineralized with 50% citric acid (pH 1.0) for 3 minutes (test group). The other half received no demineralization (control group). The bone grafts were immobilized by a resorbable membrane glued to the recipient bed with cyanoacrylate. After 7, 30, and 90 days, specimens (n = 6) were obtained for light microscopy. Data from qualitative analysis and computerized histomorphometry were statistically processed at a significance level of 5%. Results: Osteogenesis was not seen at the interface after 7 days. After 30 days, the test group showed 34.39% ± 13.4% of the interface area filled with mineralized tissue, compared to 17.14% ± 8.6% in the control group (P = 0.026). After 90 days, the mean percentages of mineralized tissue at the interface in the test and control specimens were 54.00% ± 11.23% and 38.65% ± 7.76% (P = 0.041), respectively. Within groups, a higher percentage of the area filled with mineralized tissue was seen at 90 days compared to 30 days (P = 0.004 for control and 0.041 for test). Conclusions: Demineralization of the contacting surfaces between autologous bone graft and bone bed improved new bone formation and bone consolidation. These data need to be confirmed in humans.     

Diverse Osteoclastogenesis of Bone Marrow From Mandible Versus Long Bone

Background: Mandibles (MB) and maxillae possess unique metabolic and functional properties and demonstrate discrete responses to homeostatic, mechanical, hormonal, and developmental stimuli. Osteogenic potential of bone marrow stromal cells (BMSCs) differs between MB versus long bones (LB). Furthermore, MB‐ versus LB‐derived osteoclasts (OCs) have disparate functional properties. This study explores the osteoclastogenic potential of rat MB versus LB marrow in vitro and in vivo under basal and stimulated conditions. Methods: Bone marrow from rat MB and LB was cultured in osteoblastic or osteoclastic differentiation media. Tartrate‐resistant acid phosphatase (TRAP) staining, resorption pit assays, and real‐time polymerase chain reaction were performed. Additionally, osmotic mini‐pumps were implanted in animals, mandibles and tibiae were isolated, and multinucleated cells (MNCs) were measured. Results: MB versus LB marrow cultures that were differentiated with receptor activator of nuclear factor‐κB ligand (RANKL) and macrophage colony‐stimulating factor produced more TRAP⁺ MNCs and greater resorptive area. To explore MB versus LB BMSC‐supported osteoclastogenesis, confluent BMSCs were cultured with parathyroid hormone (PTH), 1,25‐dihydroxyvitamin D₃ (1,25D₃), or PTH+1,25D₃. 1,25D₃‐ or PTH+1,25D₃‐treated LB BMSCs expressed significantly higher RANKL and lower osteoprotegerin (OPG) mRNA and increased RANKL:OPG ratio. When whole marrow was cultured with PTH+1,25D₃, more TRAP⁺ MNCs were seen in LB versus MB cultures. Ultimately, rats were infused with PTH+1,25D₃, and MB versus tibia MNCs were measured. Hormonal stimulation increased osteoclastogenesis in both MB and tibiae. However, higher TRAP⁺ MNC numbers were observed in tibiae versus MB under basal and hormonal stimulation. Conclusion: Collectively, these data illustrate differences of both osteoclastogenic potential and OC numbers of MB versus LB marrow.